Product Information
Name:(9E)-9-[O-[(4-Methylphenyl)sulfonyl]oxime] Erythromycin
Controlled Product
Synonyms:
- [(E)-[(2R,3S,4R,5S,7R,9R,10R,11S,12S,13R)-10-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,9-trihydroxy-12-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-14-oxo-oxacyclotetradec-6-ylidene]amino] 4-methylbenzenesulfonate
Brand:TRC
Description:Applications (9E)-9-[O-[(4-Methylphenyl)sulfonyl]oxime] Erythromycin is an intermediate in the synthesis of Erythromycin A 9,11-Imino Ether (E650025). Erythromycin A 9,11-Imino Ether is an impurity in the synthesis of Erythromycin (E649950), a macrolide antibiotic with broad spectrum of antibacterial activity.References Zhang, L. et al.: J. Antibio., 64, 243 (2011); Koch, W.L., et al.: Anal. Profiles Drug Subs., 8, 157 (1979)
Notice:Our products are intended for lab use only. For any other use, please contact us.
Chemical properties
Molecular weight:903.128
Formula:C44H74N2O15S
Color/Form:Neat
InChI:InChI=1S/C44H74N2O15S/c1-15-32-44(11,52)37(48)26(5)34(45-61-62(53,54)30-18-16-23(2)17-19-30)24(3)21-42(9,51)39(60-41-35(47)31(46(12)13)20-25(4)56-41)27(6)36(28(7)40(50)58-32)59-33-22-43(10,55-14)38(49)29(8)57-33/h16-19,24-29,31-33,35-39,41,47-49,51-52H,15,20-22H2,1-14H3/b45-34+/t24-,25-,26+,27+,28-,29+,31+,32-,33+,35-,36+,37-,38+,39-,41+,42-,43-,44-/m1/s1
InChI key:InChIKey=WAZVMUGFTJEWAB-QJIYQREHSA-N
SMILES:CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OS(=O)(=O)c2ccc(C)cc2)[C@H](C)[C@@H](O)[C@]1(C)O
Technical inquiry about: (9E)-9-[O-[(4-Methylphenyl)sulfonyl]oxime] Erythromycin
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
